TGen's platform.org social media analysis has been named a finalist for a global social influence accolade
In a significant stride towards understanding Alzheimer's disease, the Translational Genomics Research Institute (TGen) based in Phoenix, Arizona, has been shortlisted as a finalist for the CLASSY Awards. This prestigious annual event, the largest social impact awards ceremony in the United States, recognises the world's greatest champions of social progress.
TGen's nomination is for an innovative social-media investigation of Alzheimer's disease called our platform.org. This pioneering online research project aims to gather results from as many as 1 million participants, making it the first study of its kind to study millions of individuals and bring us closer to a cure for Alzheimer's.
Dr. Huentelman, the lead researcher of the our platform.org project at TGen, encourages as many participants as possible to join the study at the website. The goal of our platform.org is to better understand these processes and develop a better-informed cure for Alzheimer's.
Alzheimer's disease is a socioeconomic epidemic that affects more than 5 million Americans and costs the nation over $200 billion annually to treat. TGen collaborates with scientists and medical communities worldwide to contribute to patient care, with a focus on helping patients with cancer, neurological disorders, and diabetes.
The 5th annual CLASSY Awards will be held on May 3, 2014, at the Marriott Marquis in San Diego. Top leaders from the social sector will convene at the event to collaborate on solving social problems.
While information about the current status of our platform.org is not readily available, it is important to note that the field of Alzheimer's research remains very active. Ongoing clinical trials, new funding programs, and data-sharing initiatives continue to advance our understanding of this debilitating disease. For example, blood-based diagnostic tests are improving patient recruitment for clinical trials, potentially speeding up new drug development.
For more information about TGen, their work, and the our platform.org study, please visit www.tgen.org. Steve Yozwiak, TGen's Senior Science Writer, can be contacted at [email protected] or 602-343-8704 for further details.
The CLASSY Awards highlights the greatest champions of social progress, and TGen's nomination underscores their commitment to conducting groundbreaking research with life-changing results.
- Neurogenomics, a field of science that studies the effects of genetics on the nervous system, plays a significant role in TGen's innovative online research project, ourplatform.org, which aims to gather data from over 1 million participants to better understand Alzheimer's disease.
- The Translational Genomics Research Institute (TGen) is shortlisted for the CLASSY Awards, an annual event recognizing world champions of social progress, for their groundbreaking work in neurogenomics and health-and-wellness, particularly in the medical-conditions arena related to Alzheimer's disease and mental health.
- TGen's focus extends beyond Alzheimer's disease, as they collaborate with scientists and medical communities worldwide to contribute to patient care, especially for those dealing with cancer, neurological disorders, and diabetes, making strides in health-and-wellness and aging research.
- In the face of Alzheimer's disease, a socioeconomic epidemic affecting over 5 million Americans and costing the nation $200 billion annually, TGen's work to develop a better-informed cure for Alzheimer's is a beacon of hope, showcasing the transformative power of neurogenomics research and signifying progress in the field of neurological disorders.
